1,6-BIS(CYCLOHEXYLOXIMINOCARBONYLAMINO)HEXANE
- Product Name
- 1,6-BIS(CYCLOHEXYLOXIMINOCARBONYLAMINO)HEXANE
- CAS No.
- 83654-05-1
- Chemical Name
- 1,6-BIS(CYCLOHEXYLOXIMINOCARBONYLAMINO)HEXANE
- Synonyms
- U-57908;Rg 80267;RHC-80267;RXSVYGIGWRDVQC-UHFFFAOYSA-N;RHC-80267 - CAS 83654-05-1 - Calbiochem;1,6-bis(cyclohexyloximinocarbonyl)hexane;1,6-BIS(CYCLOHEXYLOXIMINOCARBONYLAMINO)HEXANE;1,6-Di(o-(carbamoyl)cyclohexanone oxime)hexane;1,6-bis(Cyclohexyloximinocarbonylamino)hexane, U 57908;O,O'-[1,6-Hexanediylbis(iminocarbonyl)]dioximecyclohexanone
- CBNumber
- CB9686432
- Molecular Formula
- C20H34N4O4
- Formula Weight
- 394.52
- MOL File
- 83654-05-1.mol
1,6-BIS(CYCLOHEXYLOXIMINOCARBONYLAMINO)HEXANE Property
- Melting point:
- 118-121℃
- Density
- 1.21±0.1 g/cm3(Predicted)
- RTECS
- GW1485000
- storage temp.
- Sealed in dry,Room Temperature
- solubility
- DMSO: 9 mg/mL
- form
- solid
- pka
- 13.81±0.46(Predicted)
- color
- white
- Stability:
- Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months
Safety
- Safety Statements
- 22-24/25
- WGK Germany
- 3
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- R2028
- Product name
- RHC 80267
- Purity
- ≥98% (HPLC), solid
- Packaging
- 5mg
- Price
- $117
- Updated
- 2024/03/01
- Product number
- 554994
- Product name
- RHC-80267
- Packaging
- 10mg
- Price
- $159
- Updated
- 2024/03/01
- Product number
- J67323
- Product name
- RHC-80267, 98%
- Packaging
- 10mg
- Price
- $138
- Updated
- 2023/06/20
- Product number
- 16432
- Product name
- RHC-80267
- Purity
- ≥95%
- Packaging
- 5mg
- Price
- $33
- Updated
- 2024/03/01
- Product number
- 16432
- Product name
- RHC-80267
- Purity
- ≥95%
- Packaging
- 10mg
- Price
- $53
- Updated
- 2024/03/01
1,6-BIS(CYCLOHEXYLOXIMINOCARBONYLAMINO)HEXANE Chemical Properties,Usage,Production
Description
RHC-80267 (83654-05-1) inhibits DAG Lipase activity in a variety of cell types and tissues, including canine platelets, bovine adrenal chromaffin cells, human adrenal glomerulosa cells, rat thyroid lobes and pancreatic minilobules. IC50 in canine platelets is 4 μM.1
Uses
RHC-80267 is a selective inhibitor of DAG lipase, which plays an important role in the production of arachidonic acid.
Definition
ChEBI: N-[6-[[(cyclohexylideneamino)oxy-oxomethyl]amino]hexyl]carbamic acid (cyclohexylideneamino) ester is a carbamate ester and an organonitrogen compound.
General Description
Selective inhibitor of DAG lipase activity in canine platelets (IC50 = 4 nM) and in a variety of mammalian cells. Also inhibits glucose- and carbachol-induced insulin release from intact islets. An inhibitor of Angiotensin II (Cat. No. 05-23-0101) and ATP-induced synthesis of 6-keto-prostaglandin F1α.
Biological Activity
Inhibitor of diacylglycerol lipase (IC 50 values are 1.1 and 4 μ M in rat cardiac myocytes and canine platelets respectively). Weakly inhibits phospholipases C and A 2 . Potentiates acetylcholine evoked relaxation in mesenteric arteries by the inhibition of cholinesterase activity (IC 50 = 4 μ M).
Biochem/physiol Actions
Product does not compete with ATP.
storage
Store at +4°C
References
1) Southerland and Amin (1982), Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors; J. Biol. Chem., 257 14006 2) Rindlisbacher et al. (1990), Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis; J. Neurochem., 54 1247 3) Chandra Sekar et al. (1987), Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors; Arch. Biochem. Biophys., 256 509 4) Levasseur et al. (1984), Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis; Prostaglandins, 27 673 5) Natarajan et al. (1988), Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors; Biochem. Biophys. Res. Commun., 156 717